Controlling Shareholder Robert Duggan Buys $13M in Open Market
PLSE sits 91% above its 52-week low of $12.56.
Summary
Controlling shareholder Robert W. Duggan purchased over $13 million of Pulse Biosciences common stock through an ATM program, reinforcing his significant stake and demonstrating strong confidence.
Key Events · Ownership and Investor Activity · PLSE
-
Significant Insider Purchase
Robert W. Duggan, the controlling shareholder, purchased 660,233 shares of common stock for approximately $13.01 million on May 11, 2026.
-
Acquisition via ATM Program
The shares were acquired through the company's existing at-the-market (ATM) equity offering program, which was recently approved for affiliate purchases.
-
Increased Controlling Stake
Duggan's beneficial ownership now stands at 49,706,423 shares, representing 71.9% of the company's outstanding common stock.
-
Strong Conviction Signal
This substantial open-market investment by the primary shareholder indicates strong confidence in Pulse Biosciences' prospects.
Analysis · PLSE · Industrial Applications And Services
Robert W. Duggan, the controlling shareholder of Pulse Biosciences, made a substantial open-market purchase of over $13 million worth of common stock. This significant investment, executed through the company's at-the-market (ATM) program, reinforces his already dominant 71.9% stake and signals strong conviction in the company's future, especially following a series of positive clinical and regulatory developments.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.2% of the 376 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLSE was trading at $23.96 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.